News

  WALTHAM, Mass., Aug 31, 2011 (GlobeNewswire via COMTEX) --

ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at three investor conferences in the coming weeks.

  --  Stifel Nicolaus Annual Healthcare Conference
9:10 a.m. ET on
      September 7, 2011 in Boston, MA
Presenter: Gregory Perry, Executive
      Vice President and CFO

  --  William Blair 2011 Life Science Conference
10:50 a.m. ET on
      September 7, 2011 in New York, NY
Presenter: Daniel Junius,
      President and CEO

  --  Morgan Stanley Global Healthcare Conference
2:45 p.m. ET on
      September 14, 2011 in New York, NY
Presenter: Daniel Junius,
      President and CEO

The webcast of each presentation can be accessed live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: ImmunoGen, Inc.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153